Opinion

Video

EMERALD Study Design and Results for Elacestrant 

Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.

  1. Please provide some background on the EMERALD trial evaluating elacestrant in HR+ HER2- mBC as well as subgroup data in patients with visceral metastases (Shah et al. J Clin Oncol. 2024
    • How have the EMERALD trial impacted your use of Elacestrant in clinical practice, particularly in terms of patients’ selection and treatment sequencing?
    • What are your impressions of the overall and subgroup data from EMERALD? Does it expand the ideal patient population for elacestrant?
    • For a patient with metastatic breast cancer to bones, liver, and lungs who has an ESR1 mutation, how does this inform treatment selection between continuing endocrine therapy versus switching to other targeted agents or chemotherapy?
    • Would elacestrant be an ideal next line treatment for this patient?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Andrew Davis, MD
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Adrienne G. Waks, MD, Dana-Farber Cancer Institute
A panel of 3 experts on CLL
A panel of 3 experts on CLL
Video 8 - 2 KOLs are featured in, "Emerging Trials in the Management of HR+/HER2- mBC"